跳至主要内容
临床试验/CTRI/2019/02/017825
CTRI/2019/02/017825进行中(未招募)未知

Rotasiil® vaccine effectiveness, rotavirus gastroenteritis and intussusception surveillance study in Jharkhand, India - RVEIS

PATH0 个研究点目标入组 1,422 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)
发起方
PATH
入组人数
1,422

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • I.Rotavirus Gastroenteritis Surveillance
  • 1.Parent/LAR has provided written informed consent.
  • 2.Present to one of the surveillance sites for treatment of AGE.
  • 3.Are <5 years of age.
  • 4.Produce a stool sample during the first 48 hours after presentation and are either treated with oral or intravenous fluids at the Emergency Department and discharged home or admitted to the hospital and treated with oral rehydration or intravenous fluids.
  • II.Vaccine Effectiveness Case-Control Evaluation
  • 1.Meet the inclusion criteria and case definition for the RVGE surveillance program plus the eligible to have received at least one dose of vaccine prior to illness, i.e. age 8 weeks or older and born after February 24, 2018 (i.e., 6 weeks prior to the initial launch of Rotasiil® in Jharkhand).
  • 2.Are <2 years of age
  • 3.Residence in the state of Jharkhand.
  • III.Intussusception Surveillance:
  • 1.Parent/LAR has provided written informed consent.
  • 2.Are <2 years of age
  • 3.Born after February 24, 2018
  • 4.Meet the case definition for intussusception using the Level 1 Brighton criteria.
  • IV.Cost of illness study:
  • 1.Enrolled into either the rotavirus gastroenteritis surveillance or intussusception surveillance programs, as applicable (are <5 years of age for rotavirus AGE surveillance and < 2 years of age for IS surveillance)
  • 2.Parent willing to provide information to fill the questionnaire.

排除标准

  • I.Rotavirus Gastroenteritis Surveillance
  • 1.Are 5 or more years of age
  • 2. Unable to contact parent/LAR to obtain written informed consent.
  • 3.Admitted to another hospital for >24 hours (and subsequently transferred to the current hospital).
  • II.Vaccine Effectiveness Case-Control Evaluation
  • 1.Are age-ineligible to have received vaccine.
  • 2.Illness onset is less than 2 weeks following initial vaccination
  • 3.Vaccination record cannot be obtained either through the vaccination card or other records
  • 4.Are >2 years of age
  • 5.Participants with hospital acquired gastroenteritis
  • 6.Participants in whom rotavirus vaccination is contraindicated
  • 7.Parent/LAR unable to provide written informed consent.
  • III.Intussusception surveillance
  • 1.Parent or LAR unwilling or unable to provide written informed consent.
  • 2.If vaccination status cannot be confirmed
  • IV.Cost of illness study
  • 1.Parent or LAR unwilling or unable to provide written informed consent.

研究者

发起方
PATH

相似试验